Tata Elxsi and Dräger collaborate to drive critical care innovation in India
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
A five-day inspection was concluded successfully with no critical and no major observations raised
Subscribe To Our Newsletter & Stay Updated